대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Tacrolimus treatment of pure red cell aplasia due to anti-erythropoietin antibodies induced by COVID-19 in hemodialysis patient: A case report
저자	Yongyu Feng
출판정보	2024; 2024(1):
키워드
초록	Pure red cell aplasia (PRCA) caused by coronavirus disease 2019 (COVID-19) infection inducing anti-erythropoietin (anti-EPO) antibodies is very rarely reported. In this article, we report a case of a hemodialysis patient who developed high titers of anti-EPO antibodies leading to PRCA after successful treatment of COVID-19 infection with tacrolimus and Roxadustat. The patient was infected with COVID-19 after 1 year of EPO treatment and despite increasing frequency of subcutaneous injection of EPO, hemoglobin (Hb) levels continued to decline and the patient required frequent RBC transfusions. After ruling out other causes of anemia, laboratory tests confirmed the production of anti-EPO antibodies, so we diagnosed PRCA. Anemia remained unimproved with systemic prednisone and cyclosporine therapies. Retest positive for anti-EPO antibodies. We used tacrolimus instead of cyclosporine. No further RBC transfusions were required after 4 weeks of tacrolimus and renal anemia was corrected by treatment with Roxadustat. The anti-EPO antibodies turned negative. Although this report emphasized COVID-19 infection can induce anti-EPO antibodies, resulting in antibody-mediated PRCA, of which the associated mechanisms remain unclearly defined.
원문(PDF)	PDF 원문보기

목록

위로가기